Assessing the Role of GSK3 β and Arrestin Beta1 in Regulating Oxidative Stress that Causes Metabolic Disorders

Metabolic syndrome is intricately associated with diabetes and obesity. Elevated obesity fosters inflammation and oxidative stress, which are precursors to several problems, including elements of metabolic disorders such as insulin resistance and hyper lipidaemia. This study aims to show that the GSK3β and Arrestin beta 1 serve as effective biomarkers for predicting metabolic disorders Such as diabetes and obesity, which leads to increased oxidative stress that enhances inflammatory reactions, and this contributes to obesity and type 2 diabetes. The research was performed at Yarmouk Teaching Hospital. Out of 180 collected samples, only 135 were measured. The patients were categorized into three groups. The biomarkers Arrestien Beta 1 and GSK3β were measured by ELISA technology, the lipid profile, FBS, and total protein were assessed using a spectrophotometer. Arrestin Beta 1 and GSK3β in the serum showed a significant increase in type 2 diabetic patients with obesity compared to the group of metabolic disorders. The atherosclerosis index (AIP) was measured using a logarithm TG/HDL-cholesterol. conclude from this study the GSK3β and Arrestin beta1 serve as effective biomarkers for predicting metabolic disorders based on the results obtained Which leads to increased production of free radicals in the body, causing   diabetes, which may lead to the accumulation of glucose in the blood, which increases levels of oxidative stress. This condition leads to increased production of free radicals and reactive molecules that contribute to the activation of NF-κB inflammatory pathways, which in turn affects the metabolic balance in the body.